50806 Federal Register / Vol. 74, No. 189 / Thursday, October 1, 2009 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Function, Integration, and 

Rehabilitation Sciences Subcommittee. 

Date: October 29, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Legacy, 1775 Rockville Pike, 

Rockville, MD 20852. 

Contact Person: Anne Krey, Scientific 

Review Officer, Division of Scientific 

Review, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6100 Executive Blvd., 

Room 5B01, Bethesda, MD 20892. 301–435– 

6908. ak41o@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 25, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23723 Filed 9–30–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Reproduction, Andrology, 

and Gynecology Subcommittee. 

Date: October 30, 2009. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Dennis Leszczynski, PhD, 

Scientific Review Officer, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute, of Child Health and 

Human Development, NIH, 6100 Executive 

Boulevard, Room 5B01, Bethesda, MD 20892, 

(301) 435–2717, leszczyd@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 25, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23720 Filed 9–30–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

October 12, 2009, 8 a.m. to October 13, 

2009, 12 p.m., National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, 

MD 20892 which was published in the 

Federal Register on September 22, 2009, 

74 FR 48269–48273. 

The meeting will be held October 13, 

2009 to October 14, 2009. The meeting 

time and location remain the same. 

The meeting is closed to the public. 

Dated: September 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23597 Filed 9–30–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0281] 

Pilot Program To Evaluate Proposed 

Proprietary Name Submissions; 

Procedures To Register for 

Participation and Submit Data 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

opportunity for pharmaceutical firms 

(applicants) to participate in a voluntary 

2-year pilot program for the evaluation 

of proposed proprietary names to be 

conducted by FDA’s Center for Drug 

Evaluation and Research (CDER) and 

Center for Biologics Evaluation and 

Research (CBER). The pilot program will 

enable participating pharmaceutical 

firms to evaluate proposed proprietary 

names and submit the data generated 

from those evaluations to FDA for 

review, as outlined in the FDA concept 

paper entitled ‘‘PDUFA Pilot Project 

Proprietary Name Review.’’ This 

document describes procedures to 

register and submit data for applicants 

who wish to have their proposed 

proprietary names evaluated under the 

pilot program. 

DATES: FDA will begin accepting 

requests to register for the voluntary 

pilot program on October 1, 2009. 

ADDRESSES: Submit written requests for 

single copies of the concept paper to the 

Division of Drug Information, Center for 

Drug Evaluation and Research, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 51, rm. 2201, 

Silver Spring, MD 20993–0002, or the 

Office of Communication, Outreach and 

Development (HFM–40), Center for 

Biologics Evaluation and Research 

(CBER), Food and Drug Administration, 

1401 Rockville Pike, Rockville, MD 

20852–1448. The concept paper may 

also be obtained by mail by calling 

CBER at 1–800–835–4709 or 301–827– 

1800. Send two self-addressed adhesive 

labels to assist the office in processing 

your requests. Requests should be 

identified with the docket number 

found in brackets in the heading of this 

document. See the SUPPLEMENTARY


PWALKER on DSK8KYBLC1PROD with NOTICES